Commentary: Monsanto May Be Counting Its ChickensRichard A. Melcher
In his optimistic moments, Robert B. Shapiro likes to compare his agriculture and pharmaceutical company to Microsoft Corp. and Intel Corp. Monsanto Co. is providing the chemical equivalent of chips and operating systems in genetically engineered seeds licensed to farmers. But perhaps Shapiro should compare Monsanto to medical biotech--an industry that for two decades has shown huge promise, soaked up billions in investment, and produced only a handful of winning products.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- The Latest on the Political Turmoil in Zimbabwe
- Goldman Sachs Sees Four 2018 Fed Rate Hikes as U.S. Growth Gains
- Norway Idea to Exit Oil Stocks Is ‘Shot Heard Around the World’
- Tesla Unveils ‘World’s Fastest Production Car’ and Electric Big Rig
- Norway Oil Bosses Insist End Isn't Nigh After $35 Billion Shock